Wednesday, November 22, 2017

AMBANK TRANSFORMERS: "THE LAST KNIGHT CAMPAIGN" LUCKY AMBANK CUSTOMER WINS THE GRAND PRIZE

KUALA LUMPUR, Nov 21 (Bernama) -- Mr Thomas Ho from Cheras, Kuala Lumpur walked away with a brand new Mercedes-AMG A45 as the Grand Prize winner of the AmBank Transformers: The Last Knight Campaign. Mr Ho, a 26-year-old cost manager, received the prize at the prize presentation ceremony held in Kuala Lumpur on Friday, 17 November 2017.

Present at the prize giving ceremony were Dato’ Sulaiman Mohd Tahir, Group Chief Executive Officer, AmBank Group, Jade Lee, Managing Director, Retail Banking, AmBank (M) Berhad, Anthony Chin, Deputy Managing Director, Retail Banking, AmBank (M) Berhad and Syed Anuar Syed Ali, Head, Group Corporate Communications & Marketing, AmBank Group.
                                                                                              
The AmBank-Transformers Spend and Deposit Campaign was introduced to reward all existing and new AmBank credit card, debit card and deposit customers. Every spent of RM50 in a single receipt via a debit or credit card entitled customers to 10 entries, while every new approved card and every incremental deposit of RM2,000 in Current or Savings account or Fixed deposit account earned them 50 entries. Customers were only required to register their interest to participate via a one-time SMS.

“AmBank is consistently creating new avenues in demonstrating our appreciation to our valued customers. We believe in rewarding our valued customers and we are delighted to share this joyous occasion with all of our winners for their continuous support towards AmBank. Our heartiest congratulations to everyone and a big gratitude to all our customers for their overwhelming response during the AmBank’s Transformers: The Last Knight Campaign,” said Dato’ Sulaiman Mohd Tahir, Group Chief Executive Officer, AmBank Group.

The first prize winner was presented to Ms Tang Chui Lang, who won a five-day and four-night VIP tour for four persons to Los Angeles’ Paramount Studios which includes an iconic ‘Bumblebee’ driving experience, while the second prize of a four-night theme park experience for four persons in Osaka, Japan won by Ms Lu Yuen Seah.

“I am very excited with this win and it was an unbelievable experience when I was informed by AmBank that I had won a brand new Mercedes-AMG A45,” said a very contented Thomas Ho. 

An excited Ms Tang who won the first prize said,’ I didn’t believe that I won until I actually came here to receive the prize and we are planning to travel to Los Angeles in March 2018. I will definitely continue to bank with AmBank”.

“I am very happy to win this prize from AmBank, a trip for four persons to Osaka, Japan. I have been using AmBank services for more than 15 years”, said a visibly excited Ms Lu Yuen Seah, the second prize winner.

Weekly prizes worth of RM100 as well as Daily prizes of a pair of movie tickets were also presented to the winners throughout the campaign period which ran from 15 May till 31 August 2017. The winners were selected based on an automated randomisation system where shortlisted customers who successfully answered simple questions were accorded with the prizes.

About AmBank Group

AMMB Holdings Berhad is the holding company of AmBank Group and has been listed on the Main Market of Bursa Malaysia since 1988. It is the sixth largest banking group by assets in Malaysia, with a market capitalisation of around RM14 billion and assets of RM134.8 billion at 31 March 2017.

AmBank Group is one of Malaysia’s premier financial solutions groups with 42 years of experience in supporting Malaysians in their economic development. AmBank Group offers a wide range of both conventional and Islamic financial solutions and services, including wholesale banking, retail banking, investment banking, underwriting of general insurance, life assurance and takaful, stock and share broking, futures broking, investment advisory and management services in assets, real estate investment trust and unit trusts.

The Group’s purpose to help individuals and businesses in Malaysia grow and win together shows our renewed vision to support and empower our customers and our people to achieve their aspirations. This purpose underpins the Group’s holistic “Top Four” Aspiration, focused on sustenance, improvement and growth in key segments and products as well as our role as an Employer. AmBank Group – a modern Malaysian diversified financial solutions partner that understands and meets the diverse needs of modern Malaysians.

AmBank’s Digital Journey is about making banking an easy, simple and fast experience for its valued customers across all touch points; branches, telephone, machines, online, mobile or even right in their lifestyle-ecosystem wherever and whenever they need to perform a banking transaction. The Group is now accelerating the next phase of its digital capabilities with a Group-Wide digital roadmap that focuses on integrating its services into the daily lives of its customers in an innovative and practical manner. In its latest offering. AmBank is the pioneer bank to introduce Malaysia’s first Digital Auto Finance Instant Approval service, through the Mobile Application Terminal (MAT).

The Australia and New Zealand Banking Group (ANZ) is the most substantial shareholder in the AmBank Group (holding 23.8%) and provides support in Board and senior management representations, risk and financial governance, products offering and new business developments. In the general insurance business, the Group has partnered with Insurance Australia Group Ltd (IAG). In the life assurance and family takaful businesses, the Group has a partnership with MetLife International Holdings Inc (MetLife). The Group benefits in terms of expertise transfer from IAG and MetLife.

For more information, please visit www.ambankgroup.com

SOURCE: AmBank Group

FOR MORE INFORMATION PLEASE CONTACT:
Name : Syed Anuar Syed Ali

Head, Group Corporate Communications and Marketing
AmBank Group
Tel : 03-2036 1703
Email : sasa@ambankgroup.com 


--BERNAMA

Tuesday, November 21, 2017

TELSTRA AND SIGMA SYSTEMS TO PRESENT CATALOG-DRIVEN DYNAMIC OFFER CREATION AT TM FORUM LIVE! ASIA

TORONTO, Nov 21 (Bernama-BUSINESS WIRE) -- Sigma Systems, the global leader in catalog-driven software, announced today that it will be presenting at TM Forum Live! Asia in partnership with Telstra, Australia’s leading telecommunications and technology company.
 
Sigma’s Chief Technology Officer (CTO), Catherine Michel, will be on stage with Telstra's Chief Technology Officer (Customer), Dr. Fawad Nazir, to discuss why traditional service providers must adopt a “digital native” mindset and the corresponding operational agility to thrive in a digital economy. The ability to create and launch new offers in minutes, rather than months, and rapidly enable new business models is critical to an operator’s success.
 
“Sigma Catalog creates the ability to sell through and then orchestrate the fulfillment of an order from different channels into the full B/OSS stack and across various delivery networks. The product’s Offer Canvas capability allows businesses to ‘componentize’ whatever types of service capability it offers into entities that are immediately operational in their systems and networks,” says Catherine Michel, Sigma Systems CTO.
 
The presentation will take place on Wednesday December 6, 2017 at 2:25pm. To learn more about Sigma’s presence at TM Forum Live! Asia, please click here.

http://mrem.bernama.com/viewsm.php?idm=30615

FLYWIRE CAPTURES GLOBAL FINTECH AWARD IN SINGAPORE

FLYWIRE CAPTURES GLOBAL FINTECH AWARD IN SINGAPORE

OCTAPHARMA DONATES 30.5 MILLION INTERNATIONAL UNITS OF ITS MEDICINE NUWIQ TO TREAT PEOPLE WITH HAEMOPHILIA IN DEVELOPING COUNTRIES

LACHEN, Switzerland, Nov 21 (Bernama-BUSINESS WIRE) -- 2017: Octapharma is pleased to announce the completion of a charitable donation of 30.5 million international units of its human cell-line derived recombinant factor VIII product, Nuwiq®, in collaboration with Project SHARE, North Andover, Massachusetts (USA).
 
This press release features multimedia. View the full release here: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=51718944&lang=en      
 
Up to 75% of the world's estimated 400,000 people with haemophilia have little or no access to treatment that resolves life- and limb-threatening bleeds, and enables surgery and rehabilitation. A humanitarian program, Project SHARE facilitates the donation of blood-clotting factor products for the treatment of people with haemophilia in need of factor replacement therapy in countries where these medicines are scarce or still unavailable.

http://mrem.bernama.com/viewsm.php?idm=30612

MUCH-ANTICIPATED CHTF 2017 TOP 10 PRODUCTS ARE UNVEILED

SHENZHEN, China, Nov 20 (Bernama-BUSINESS WIRE) -- The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City.

A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online.

The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other health data, the 3D bio-printer that can print a functioning ovary, the clean energy air-conditioning station, the smart security system for kids, the 6.01-inch full screen, the flexible fast-charge battery, the 3-G gene sequencer, the automatic pilot level 4 solution, and anti-haze window screen.

Also unveiled at the ceremony were the “Top 8 Eye-Catching Products” which represent the taste of the public. Winners included the 3D motion-activated camera and the unmanned surface patrol vehicle.

As a warmup activity before CHTF 2017’s official kick-off, Top 10 Products gained much public attention for the fair. See you at CHTF 2017!

http://mrem.bernama.com/viewsm.php?idm=30595]
 

MADISON REALTY CAPITAL PROVIDES $64.0 MILLION CONSTRUCTION FINANCING FOR 200 KENT AVENUE DEVELOPMENT IN WILLIAMSBURG, BROOKLYN

Experienced Local Developer Taps MRC for Construction Loan on Grocery-Anchored Mixed-Use Project Located on Full Block Site in One of New York’s Most Exciting Neighborhoods

NEW YORK, Nov 20 (Bernama-BUSINESS WIRE) -- Madison Realty Capital (MRC) announced the closing of a $64.0 million construction loan for 200 Kent Avenue, a 117,326 square foot mixed-use development located in Williamsburg, Brooklyn. The retail portion of the property, which will include over 600 feet of frontage, will be anchored by a popular national grocery chain. Overall, the project will offer 50,101 square feet of retail space, 22,055 square feet of office and restaurant space, and 45,170 square feet of parking.

http://mrem.bernama.com/viewsm.php?idm=30600

Monday, November 20, 2017

NEURALSTEM ANNOUNCES PRESENTATION OF CLINICAL DATA FOR NSI-189 IN MAJOR DEPRESSIVE DISORDER AT THE UPCOMING AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING

GERMANTOWN, Md., Nov 17 (Bernama-GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that data from the Company’s Phase 2 study of NSI-189 in patients with major depressive disorder will be presented at the 56th American College of Neuropsychopharmacology (ACNP) Annual Meeting, which is being held in Palm Springs, California from December 3-7, 2017.

Poster presentation details are as follows:

Title: A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189 Phosphate, a Neurogenic Compound Among Out-Patients with Major Depressive Disorder
Abstract Number: M79
Session Title: Poster Session I
Presenter: George Papakostas, M.D., Massachusetts General Hospital
Date and Time: Monday, December 4, 2017, 5:30 PM – 7:30 PM PT

About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. NSI-189 is a small molecule in clinical development for major depressive disorder (MDD) and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes, and stroke.

NSI-566 is a stem cell therapy being tested for treatment of paralysis in stroke, chronic spinal cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS). Neuralstem’s diversified portfolio of product candidates is based on its proprietary neural stem cell technology.

Cautionary Statement Regarding Forward Looking Information
This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the Annual Report on Form 10-K for the year ended December 31, 2016, and Form 10-Q for the three and nine months ended September 30, 2017, filed with the Securities and Exchange Commission (SEC), and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.

Contact:

Kimberly Minarovich
Argot Partners (Investor Relations)
212-600-1902
kimberly@argotpartners.com

Source : Neuralstem, Inc.

--BERNAMA